Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease
Objective: The aim of this study was to explore the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on…Effects of Motor Subtype Stability on Non-Motor Symptoms in Early Parkinson’s Disease
Objective: To determine the effects of motor subtypes’ stability on non-motor symptoms (NMS) over three years in early Parkinson’s disease (PD). Background: Research have found…Anxiety in Parkinson’s disease is associated with changes in brain structural connectivity
Objective: The aim of this study was to identify White Matter (WM) changes by comparing Parkinson's disease (PD) patients with and without anxiety, using diffusion-tensor…Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson’s disease
Objective: To assess the interplay of polygenic dopamine risk scores and psychiatric symptoms in the development of impulse control disorders (ICDs) in de novo patients…Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)
Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative
Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…Healthcare experiences of People with Parkinson’s Disease (PwP) during COVID-19 pandemic
Objective: To investigate how our group of PwP coped with healthcare issues during the pandemic. Background: COVID-19 pandemic led to changes in how healthcare services…Dynamic assessment of levels of depression and anxiety impairment in Parkinson’s disease
Objective: To dynamic assessment of depression and anxiety disorders in Parkinson's disease. Background: One of the most common nonmotor disturbances in Parkinson's disease (PD) is…Recruitment of Parkinson’s disease patients with mild-to-moderate anxiety into a randomized controlled trial: Experience of a large Canadian tertiary movement disorders clinic
Objective: To report our experience of recruiting Parkinson’s disease (PD) patients with mild-to-moderate anxiety into a randomized controlled trial. Background: Anxiety is a common non-motor…Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson’s disease
Objective: We aimed to investigatethe evolution of depression and anxietyin a large Parkinson's disease (PD) cohort and explore the related plasma biomarkers. Background: Depression and anxietyare common non-motor…
- 1
- 2
- 3
- …
- 14
- Next Page »